stockportfolio.pro
Zymeworks Inc. (ZYME)
Healthcare · Biotechnology · NasdaqGS
Zymeworks Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $38.95M | $26.68M | $412.48M | $76.01M | $76.30M | $105.97M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-180.55M | $-211.84M | $124.34M | $-118.67M | $-122.69M | $-81.13M |
| Net margin | -463.5% | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
Source: Zymeworks Inc. SEC filings (10-K).
Explore 6 years of Zymeworks Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ZYME in your portfolio →
Zymeworks Inc. financial history by metric
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Zymeworks Inc. — frequently asked questions
What is Zymeworks Inc.'s revenue?
Zymeworks Inc. (ZYME) reported revenue of $105.97M for fiscal year 2025, up 38.9% from the prior year, according to its SEC filings.
Is Zymeworks Inc. profitable?
No — ZYME reported a net loss of $-81.13M in fiscal 2025.
What is ZYME's P/E ratio?
Zymeworks Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Zymeworks Inc. growing?
ZYME's revenue grew at roughly 22.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Zymeworks Inc. have?
As of fiscal year 2025, ZYME carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Zymeworks Inc.'s market cap?
Zymeworks Inc. (ZYME) has a market capitalization of about $1.69B, based on the latest data in our nightly-refreshed cache.
When does Zymeworks Inc.'s fiscal year end?
ZYME's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Zymeworks Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.